AIM: Hereditary diffuse gastric cancer (HDGC) is a cancer susceptibility syndrome caused by E-cadherin germline mutations. One-third of these mutations are of the missense type, representing a burden in genetic counselling. A new germline missense mutation (P373L) was recently identified in a HDGC Italian family. The present work aimed at addressing the disease-causative nature of the P373L mutant. METHODS: Assessment of the P373L mutation effect was based on cell aggregation and invasion assays. LOH analysis at the E-cadherin locus, search for somatic E-cadherin mutations and for promoter hypermethylation were performed to identify the mechanism of inactivation of the E-cadherin wild-type allele in the tumour. RESULTS: In vitro the P373L germline mutation impaired the E-cadherin functions. E-cadherin promoter hypermethylation was observed in the tumour of the P373L mutation carrier. CONCLUSION: We conclude that the combination of clinical, in vitro and molecular genetic data is helpful for establishing an accurate analysis of HDGC-associated CDH1 germline missense mutations and subsequently for appropriate clinical management of asymptomatic mutation carriers.
AIM: Hereditary diffuse gastric cancer (HDGC) is a cancer susceptibility syndrome caused by E-cadherin germline mutations. One-third of these mutations are of the missense type, representing a burden in genetic counselling. A new germline missense mutation (P373L) was recently identified in a HDGC Italian family. The present work aimed at addressing the disease-causative nature of the P373L mutant. METHODS: Assessment of the P373L mutation effect was based on cell aggregation and invasion assays. LOH analysis at the E-cadherin locus, search for somatic E-cadherin mutations and for promoter hypermethylation were performed to identify the mechanism of inactivation of the E-cadherin wild-type allele in the tumour. RESULTS: In vitro the P373L germline mutation impaired the E-cadherin functions. E-cadherin promoter hypermethylation was observed in the tumour of the P373L mutation carrier. CONCLUSION: We conclude that the combination of clinical, in vitro and molecular genetic data is helpful for establishing an accurate analysis of HDGC-associated CDH1 germline missense mutations and subsequently for appropriate clinical management of asymptomatic mutation carriers.
Authors: Rebecca C Fitzgerald; Richard Hardwick; David Huntsman; Fatima Carneiro; Parry Guilford; Vanessa Blair; Daniel C Chung; Jeff Norton; Krishnadath Ragunath; J Han Van Krieken; Sarah Dwerryhouse; Carlos Caldas Journal: J Med Genet Date: 2010-07 Impact factor: 6.318
Authors: Dong Li; Michael E March; Paola Fortugno; Liza L Cox; Leticia S Matsuoka; Rosanna Monetta; Christoph Seiler; Louise C Pyle; Emma C Bedoukian; María José Sánchez-Soler; Oana Caluseriu; Katheryn Grand; Allison Tam; Alicia R P Aycinena; Letizia Camerota; Yiran Guo; Patrick Sleiman; Bert Callewaert; Candy Kumps; Annelies Dheedene; Michael Buckley; Edwin P Kirk; Anne Turner; Benjamin Kamien; Chirag Patel; Meredith Wilson; Tony Roscioli; John Christodoulou; Timothy C Cox; Elaine H Zackai; Francesco Brancati; Hakon Hakonarson; Elizabeth J Bhoj Journal: Hum Genet Date: 2021-04-03 Impact factor: 5.881
Authors: Keith Nykamp; Michael Anderson; Martin Powers; John Garcia; Blanca Herrera; Yuan-Yuan Ho; Yuya Kobayashi; Nila Patil; Janita Thusberg; Marjorie Westbrook; Scott Topper Journal: Genet Med Date: 2017-05-11 Impact factor: 8.822